Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Darbepoetin Alfa Risks Outweigh Benefits for Patients With CKD, Diabetes, and Anaemia: Presented at Renal Week 2009 - (DGDispatch)
    Fenofibrate May Protect Diabetics Against Loss of Renal Function: Presented at Renal Week 2009 - (DGDispatch)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    TopAbstracts in Diabetes 11/03/2009 - (DGNews)
    Paricalcitol Added to Hypertension Therapy Lowers Albuminuria in Patients With Diabetes and Chronic Kidney Disease: Presented at Renal Week 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Diabetes
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Cases in Practice: Incretin-Based Therapies for Common Patient Encounters
      Diabetes Management - Pearls of Lipid Control
      Obesity Management in Patients with Type 2 Diabetes

      Webcasts/CME archive

       Recent cases - Diabetes
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Compound Heterozygous Mutation of Aquaporin 2 Gene in Woman Patient with Congenital Nephrogenic Diabetes Insipidus

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Repaglinide Potency Greatly Increased When Combined With Gemfibrozil

        A DGReview of :"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide"
        Diabetologia

        04/24/2003
        By David Loshak


        A potentially hazardous interaction between gemfibrozil, a fibrate, and repaglinide, an oral hypoglycaemic agent, has been found by Finnish specialists.

        Gemfibrozil, especially in combination with itraconazole, greatly increased and prolonged the blood glucose-lowering effect of repaglinide, they found. Repaglinide thus became a long-acting and stronger anti-diabetic.

        Clinicians should avoid using the two medications together, the specialists warned. If the combination is necessary, repaglinide dosage should be greatly reduced and blood glucose concentrations carefully monitored.

        The specialists, clinical pharmacologists at Helsinki University Central Hospital, Finland, studied possible interactions of gemfibrozil, itraconazole and their combination with repaglinide in a randomised crossover study.

        They enrolled 12 healthy volunteers who were given either gemfibrozil 600 mg., itraconazole 100 mg. (first dose 200 mg.), gemfibrozil and itraconazole together or placebo, all twice daily for 3 days. On the third day, the volunteers took a 0.25 mg. dose of repaglinide.

        Plasma drug and blood glucose concentrations were followed for 7 hours and serum insulin and C-peptide concentrations for 3 hours post-dose.

        Gemfibrozil raised the area under the plasma concentration-time curve of repaglinide by 5.5-15.0 times and prolonged its half-life from 1.3 to 3.7 hours.

        Itraconazole alone raised repaglinide's area under the plasma concentration-time curve by 1.1-1.9 times. But, the gemfibrozil-itraconazole combination raised it by 12.9-24.7 times and prolonged repaglinide's half-life to 6.1 hours.

        Gemfibrozil increased plasma repaglinide concentration at 7 hours by 28.6 times. The gemfibrozil-itraconazole combination increased plasma repaglinide concentration at 7 hours by 70.4 times.
        Diabetologia 2003;46:347-351. "Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send